Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 57
Filtrar
1.
Neuroreport ; 29(1): 54-58, 2018 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-29135714

RESUMEN

It has been suggested that serotonin (5-HT) may be implicated in functional recovery after stroke; however, the underlying molecular mechanisms remain unknown. Here, the role of 5-HT was verified using ritanserin, a potent 5-HT2A receptor antagonist, and protein expression and modification were analyzed to further understand the association between paralysis recovery and molecular mechanisms in the brain. Experimental cerebral cortex infarctions were induced by photothrombosis in rats. Voluntary exercise was initiated 2 days after surgery. Motor performance was then measured using the rotarod test. Differences in protein expression and phosphorylation in the perilesional cortex were analyzed using western blot. In behavioral evaluations, performance in the rotarod test was significantly increased by exercise. However, there was a significantly lower value in time until falling after combined exercise and ritanserin administration compared with that of exercise alone. Protein expression analysis revealed that phosphorylation of protein kinase C (PKC) α, PKCε, and growth-associated protein 43 (GAP43) was significantly upregulated by exercise. These effects were attenuated by ritanserin administration. These data suggest that 5-HT may be related to the underlying mechanisms of exercise-dependent paralysis recovery, that is, exercise-dependent plasticity through the phosphorylation of PKC and GAP43.


Asunto(s)
Infarto Cerebral/complicaciones , Infarto Cerebral/tratamiento farmacológico , Recuperación de la Función/efectos de los fármacos , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Animales , Infarto Cerebral/rehabilitación , Modelos Animales de Enfermedad , Proteína GAP-43/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Locomoción/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Condicionamiento Físico Animal/métodos , Proteína Quinasa C/metabolismo , Ratas , Ratas Sprague-Dawley
2.
Expert Rev Anti Infect Ther ; 14(2): 177-91, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26655489

RESUMEN

Progressive multifocal encephalopathy (PML) caused by JC virus was frequently encountered in AIDS patients before combination antiretroviral therapy (cART). Incidence decreased and the outcome improved with cART. The immune reconstitution with cART is beneficial for HIV-infected patients and is an effective treatment for PML. However, when it is excessive an inflammatory response immune syndrome might occur with deterioration of PML. So far, no specific therapy has proven efficacious in small clinical trials in spite of some optimistic case reports. Combination of drugs targeted at different stages of JC virus life cycle seems to have a better effect. Passive and active immune therapies, immune competence "boosters" appear promising. New future approaches such as gene editing are not far away.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa/métodos , Antivirales/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Síndrome Inflamatorio de Reconstitución Inmune/inducido químicamente , Leucoencefalopatía Multifocal Progresiva/tratamiento farmacológico , Antagonistas de la Serotonina/uso terapéutico , Cidofovir , Coinfección , Citarabina/uso terapéutico , Citosina/análogos & derivados , Citosina/uso terapéutico , Infecciones por VIH/complicaciones , Infecciones por VIH/inmunología , Humanos , Síndrome Inflamatorio de Reconstitución Inmune/inmunología , Leucoencefalopatía Multifocal Progresiva/complicaciones , Leucoencefalopatía Multifocal Progresiva/inmunología , Mefloquina/uso terapéutico , Mianserina/análogos & derivados , Mianserina/uso terapéutico , Mirtazapina , Organofosfonatos/uso terapéutico , Ritanserina/uso terapéutico
3.
Neuropharmacology ; 62(1): 322-31, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21855555

RESUMEN

Earlier studies have demonstrated that the agonists of the mGlu(2/3) receptors produced anxiolytic actions after peripheral administration. However, the mechanism of their action is still not clear. Therefore the aim of the present study was to specify the role of the GABAergic and serotonergic system in the mechanism of the anxiolytic activity of group II mGlu receptor activators by using the stress induced hyperthermia test (SIH) in singly housed mice. We used an orthosteric mGlu(2/3) receptor agonist, LY379268, which induced anti-hyperthermic efficacy in the doses of 1-5mg/kg (73% of inhibition after a highest dose). The effect of the second ligand used, a mGlu(2) receptor positive modulator (PAM), LY487379, was observed in a dose range of 0.5-5mg/kg and reached 53% of the inhibition. The blockade of GABAergic system by GABA(A) receptor antagonist flumazenil (10mg/kg) or GABA(B) receptor antagonist CGP55845 (10mg/kg), and the blockade of serotonergic system by 5-HT(1A) receptor antagonist WAY100635 (0.1 and 1mg/kg) or 5-HT(2A/2C) receptor antagonist ritanserin (0.5mg/kg) had no influence on the anti-hyperthermic effect induced by effective dose of LY379268. However, the action of the effective dose of LY487379 was enhanced when co-administered with flumazenil, WAY100635 (0.1mg/kg) and ritanserin. Similar results were observed for the subeffective dose of LY379268 (0.5mg/kg). WAY100635 in a dose of 1mg/kg did not induce any enhancing effect on the activity of compounds. Therefore, it seems that the antagonism towards GABA(A) receptors, presynaptic 5-HT(1A) and postsynaptic 5-HT(2A/2C) receptors is responsible for the phenomenon. This article is part of a Special Issue entitled 'Anxiety and Depression'.


Asunto(s)
Aminoácidos/uso terapéutico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Agonistas de Aminoácidos Excitadores/uso terapéutico , Fiebre/tratamiento farmacológico , Piridinas/uso terapéutico , Receptores AMPA/metabolismo , Sulfonamidas/uso terapéutico , Análisis de Varianza , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Fiebre/etiología , Flumazenil/uso terapéutico , Antagonistas del GABA/uso terapéutico , Moduladores del GABA/uso terapéutico , Masculino , Ratones , Ácidos Fosfínicos/uso terapéutico , Piperazinas/uso terapéutico , Propanolaminas/uso terapéutico , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Aislamiento Social , Estrés Psicológico/complicaciones
4.
Neuropharmacology ; 59(1-2): 31-6, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20361986

RESUMEN

Clinical observations have suggested that ritanserin, a 5-HT(2A/C) receptor antagonist may reduce motor deficits in persons with Parkinson's Disease (PD). To better understand the potential antiparkinsonian actions of ritanserin, we compared the effects of ritanserin with the selective 5-HT(2A) receptor antagonist M100907 and the selective 5-HT(2C) receptor antagonist SB 206553 on motor impairments in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP-treated mice exhibited decreased performance on the beam-walking apparatus. These motor deficits were reversed by acute treatment with L-3,4-dihydroxyphenylalanine (levodopa). Both the mixed 5-HT(2A/C) antagonist ritanserin and the selective 5-HT(2A) antagonist M100907 improved motor performance on the beam-walking apparatus. In contrast, SB 206553 was ineffective in improving the motor deficits in MPTP-treated mice. These data suggest that 5-HT(2A) receptor antagonists may represent a novel approach to ameliorate motor symptoms of Parkinson's disease.


Asunto(s)
Discinesias/tratamiento farmacológico , Trastornos Parkinsonianos/tratamiento farmacológico , Antagonistas del Receptor de Serotonina 5-HT2 , Antagonistas de la Serotonina/uso terapéutico , Animales , Antiparkinsonianos/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Evaluación de la Discapacidad , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Fluorobencenos/administración & dosificación , Fluorobencenos/uso terapéutico , Indoles/administración & dosificación , Indoles/uso terapéutico , Levodopa/uso terapéutico , Masculino , Ratones , Ratones Endogámicos C57BL , Enfermedad de Parkinson , Trastornos Parkinsonianos/metabolismo , Piperidinas/administración & dosificación , Piperidinas/uso terapéutico , Piridinas/administración & dosificación , Piridinas/uso terapéutico , Ritanserina/administración & dosificación , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/administración & dosificación , Resultado del Tratamiento
5.
Prog Neuropsychopharmacol Biol Psychiatry ; 32(8): 1879-83, 2008 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-18801405

RESUMEN

It was reported that ritanserin, a 5HT2A/2C antagonist, improves negative symptoms when added to neuroleptics in inpatients with predominantly negative symptoms. Nevertheless, the results of published studies are contradictory so far. This study was designed to investigate the effect of ritanserin added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double blind and randomized clinical trial. Eligible participants in this study were 40 patients with chronic schizophrenia. All patients were inpatients and were in the active phase of the illness, and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion, 20 to risperidone 6 mg/day plus ritanserin 12 mg/day (6 mg bid) and 20 to risperidone 6 mg/day plus placebo. The principal measure of the outcome was Positive and Negative Syndrome Scale (PANSS). Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and ritanserin showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores. The present study indicates ritanserin as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. Nevertheless, results of larger controlled trials are needed, before recommendation for a broad clinical application can be made.


Asunto(s)
Antipsicóticos/uso terapéutico , Ritanserina/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/fisiopatología , Adulto , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Masculino , Estudios Prospectivos , Escalas de Valoración Psiquiátrica , Psicopatología , Estudios Retrospectivos , Risperidona/uso terapéutico , Resultado del Tratamiento , Adulto Joven
6.
Biochem Pharmacol ; 75(1): 34-56, 2008 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-17880925

RESUMEN

The past decade has seen an expansion of research and knowledge on pharmacotherapy for the treatment of alcohol dependence. The Food and Drug Administration (FDA)-approved medications naltrexone and acamprosate have shown mixed results in clinical trials. Oral naltrexone and naltrexone depot formulations have generally demonstrated efficacy at treating alcohol dependence, but their treatment effect size is small, and more research is needed to compare the effects of different doses on drinking outcome. Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size. In U.S. trials, acamprosate has not proved to be efficacious. Research continues to explore which types of alcohol-dependent individual would benefit the most from treatment with naltrexone or acamprosate. The combination of the two medications demonstrated efficacy for treating alcohol dependence in one European study but not in a multi-site U.S. study. Another FDA-approved medication, disulfiram, is an aversive agent that does not diminish craving for alcohol. Disulfiram is most effective when given to those who are highly compliant or who are receiving their medication under supervision. Of the non-approved medications, topiramate is among the most promising, with a medium effect size in clinical trials. Another promising medication, baclofen, has shown efficacy in small trials. Serotonergic agents such as selective serotonin reuptake inhibitors and the serotonin-3 receptor antagonist, ondansetron, appear to be efficacious only among certain genetic subtypes of alcoholic. As neuroscientific research progresses, other promising medications, as well as medication combinations, for treating alcohol dependence continue to be explored.


Asunto(s)
Alcoholismo/tratamiento farmacológico , Acamprosato , Animales , Baclofeno/uso terapéutico , Disulfiram/uso terapéutico , Fructosa/análogos & derivados , Fructosa/uso terapéutico , Humanos , Naltrexona/administración & dosificación , Naltrexona/uso terapéutico , Ondansetrón/uso terapéutico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Ritanserina/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Taurina/análogos & derivados , Taurina/uso terapéutico , Topiramato
7.
Dig Dis Sci ; 52(9): 2351-8, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17420952

RESUMEN

The protective effect of 5-HT(2) receptor blockade with ketanserin or ritanserin against cadmium liver injury was investigated. Male Wistar rats were injected intraperitoneally with a sublethal dose of cadmium (3.5 mg/kg body weight). Rats were treated with normal saline (group I), ketanserin (3 mg/kg body weight; group II), or ritanserin (3 mg/kg body weight; group III) 2 hr prior and 4 hr after cadmium administration and killed at different time points. Hematoxylin/eosin-stained liver sections were assessed for necrosis, apoptosis, peliosis, mitoses, and inflammatory infiltration. Apoptosis was also quantified by the TUNEL assay. Nonparenchymal liver cells and activated Kupffer cells were identified histochemically. Necrosis, hepatocyte apoptosis, nonparenchymal cell apoptosis, and macroscopic and microscopic peliosis were markedly reduced or minimized in ketanserin- or ritanserin-treated rats. The observed protective effect was almost identical for both ketanserin and ritanserin administration. 5-HT(2) receptor blockade exerts a protective effect against acute cadmium-induced hepatotoxicity.


Asunto(s)
Ketanserina/uso terapéutico , Fallo Hepático Agudo/tratamiento farmacológico , Ritanserina/uso terapéutico , Antagonistas del Receptor de Serotonina 5-HT2 , Antagonistas de la Serotonina/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Cadmio/toxicidad , Modelos Animales de Enfermedad , Etiquetado Corte-Fin in Situ , Fallo Hepático Agudo/inducido químicamente , Fallo Hepático Agudo/metabolismo , Masculino , Ratas , Ratas Wistar , Receptores de Serotonina 5-HT2/metabolismo , Resultado del Tratamiento
8.
Behav Brain Res ; 161(2): 286-90, 2005 Jun 20.
Artículo en Inglés | MEDLINE | ID: mdl-15922055

RESUMEN

Administration of benzodiazepines is known to be associated with tolerance and a withdrawal syndrome on abrupt cessation. The aetiology of the withdrawal syndrome is not known but a role for the serotonin (5HT) system is suspected. The aim of the current study was to investigate the usefulness of 5-HT2 antagonists in the treatment of benzodiazepine withdrawal syndrome in the rat. Male Wistar rats were treated with either diazepam (4 mg/kg) or vehicle for 14 days, then abruptly withdrawn for 24h. Animals were tested in the social interaction paradigm and elevated plus maze. Some diazepam-withdrawn rats were pre-treated with 5HT2 antagonists 60 min before behavioural testing. Acute withdrawal from benzodiazepines significantly reduced social interaction between pairs compared to vehicle or diazepam-treated animals. Similarly, for the elevated plus maze withdrawn animals made fewer entries and spent less time on the open arms than did vehicle or diazepam-treated animals. Single doses of 5-HT2 antagonists, mianserin (5mg/kg) and ritanserin (1mg/kg), effectively ameliorated withdrawal anxiety in the rat, returning behavioural function in the social interaction test and elevated plus maze to levels comparable to vehicle-treated animals.


Asunto(s)
Ansiolíticos/efectos adversos , Diazepam/efectos adversos , Mianserina/uso terapéutico , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/etiología , Animales , Ansiedad/tratamiento farmacológico , Conducta Animal , Modelos Animales de Enfermedad , Relaciones Interpersonales , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratas , Ratas Wistar , Factores de Tiempo
9.
Eur J Pharmacol ; 483(1): 65-9, 2004 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-14709327

RESUMEN

The effect of subchronic co-administration of ritanserin (1.5 mg/kg, i.p., twice a day) and haloperidol (1 mg/kg, i.p., twice a day) on rat vacuous chewing movements and on tyrosine hydroxylase-immunostaining was investigated. Ritanserin significantly reduced rat vacuous chewing movements observed following 2, 3 and 4 weeks of haloperidol administration and after 5 days of haloperidol withdrawal. Furthermore, ritanserin prevented the reduction of striatal tyrosine hydroxylase-immunostaining and the shrinkage of nigral dopaminergic cell bodies induced by haloperidol. The present results indicate that ritanserin may possess protective properties on both dopaminergic nigro-striatal neuron alterations and vacuous chewing movements induced by haloperidol, and provide further evidence indicating a possible association between these two haloperidol-induced effects.


Asunto(s)
Antipsicóticos/toxicidad , Antipsicóticos/uso terapéutico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Haloperidol/antagonistas & inhibidores , Haloperidol/toxicidad , Neostriado/enzimología , Ritanserina/uso terapéutico , Sustancia Negra/enzimología , Tirosina 3-Monooxigenasa/metabolismo , Animales , Tamaño de la Célula , Inmunohistoquímica , Masculino , Neostriado/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Sustancia Negra/citología , Sustancia Negra/efectos de los fármacos
10.
Eur J Pharmacol ; 486(1): 85-9, 2004 Feb 13.
Artículo en Inglés | MEDLINE | ID: mdl-14751412

RESUMEN

Early microvascular constriction following atherosclerotic plaque rupture may be mediated via serotonin and/or endothelin-1. Atherosclerotic lesions in the rabbit hindlimb underwent plaque rupture, resulting in a rapid reduction of distal flow (7.1+/-0.7 ml/min pre-rupture versus 3.6+/-0.6 ml/min post-rupture, P<0.001) and a rise in distal microvascular resistance (10.5+/-0.9 mm Hg min/ml pre-rupture versus 23.5+/-3.5 mm Hg min/ml post-rupture, P=0.01). Distal microvascular resistance remained elevated following endothelin-1 receptor antagonism and control vehicle, but normalised after serotonin receptor antagonism with ritanserin (10.5+/-0.9 mm Hg min/ml pre-rupture versus 22.2+/-6.0 mm Hg min/ml post-endothelin-1 receptor antagonism [P<0.05] versus 21.6+/-6.2 mm Hg min/ml post-control vehicle [P<0.05] versus 11.6+/-2.0 mm Hg min/ml post-ritanserin [P=NS]). Early antagonism of serotonin receptors protects against distal microvascular constriction following atherosclerotic plaque rupture.


Asunto(s)
Arteriosclerosis/tratamiento farmacológico , Ritanserina/farmacología , Antagonistas del Receptor de Serotonina 5-HT2 , Vasoconstricción/efectos de los fármacos , Animales , Arteriosclerosis/fisiopatología , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Modelos Animales de Enfermedad , Arteria Ilíaca/efectos de los fármacos , Arteria Ilíaca/fisiología , Indanos/farmacología , Microcirculación/efectos de los fármacos , Microcirculación/fisiología , Conejos , Receptores de Serotonina 5-HT2/fisiología , Ritanserina/uso terapéutico , Rotura/tratamiento farmacológico , Rotura/fisiopatología , Vasoconstricción/fisiología
11.
Pharmacopsychiatry ; 36(4): 150-5, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12905101

RESUMEN

A recent study in narcolepsy patients has shown that ritanserin, a 5HT2-antagonist, reduced wake after sleep onset times and subjective sleepiness during daytime. To assess the efficacy of this compound in a statistically sufficient number of narcoleptic patients a double-blind, placebo-controlled, European multi-center study on the effects of ritanserin on daytime sleepiness, the feeling of being refreshed in the morning, number of unwanted sleep periods and slow-wave sleep was performed. All 134 narcolepsy patients were allowed to remain on stable concomitant antidepressant, stimulant and gammahydroxybutyrate medication during the trial. Patients were randomly assigned to treatment with 5 mg or 10 mg ritanserin or placebo given once daily for 28 days. Efficacy was measured by two 40-hour polysomnographic recordings, visual analogue scales and physician, partner, parents and patient-rated sleep-wake behavior tests prior to and after the trial. Patients kept diaries on sleepiness, numbers of wanted and unwanted sleep periods, feeling of being refreshed and frequency of narcoleptic symptoms during the entire treatment period. Treatment with 5 and 10 mg ritanserin significantly improved the 'feeling of being refreshed in the morning,' but no other narcoleptic symptoms as assessed in the diary. Whereas investigators had the impression that the primary efficacy parameters were not improved by ritanserin, patients reported significant improvements in four out of six parameters, and patients partners in two out of six parameters with 5 mg ritanserin compared to placebo. Both ritanserin doses resulted in a significant increase of nocturnal slow-wave sleep (percentage of total sleep time) and a significant, dose-dependent reduction in NREM stage 1 percentage during daytime sleep. The significant polysomnographic findings were not paralleled by changes in the subjective parameters daytime sleepiness or number of unplanned sleep periods. In contrast to the first study on narcoleptic patients, ritanserin only improved one subjective parameter, but did not improve objective sleep quality or number of "sleep attacks" or reduce "wake after sleep onset" during night or daytime sleep. In conclusion, ritanserin may serve as add-on medication for the treatment of impaired sleep quality in narcoleptic patients, but not as a stimulant or hypnotic type of medication.


Asunto(s)
Narcolepsia/tratamiento farmacológico , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Adulto , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Masculino , Polisomnografía , Ritanserina/administración & dosificación , Antagonistas de la Serotonina/administración & dosificación , Sueño/efectos de los fármacos
12.
BMC Psychiatry ; 3: 7, 2003 Jun 19.
Artículo en Inglés | MEDLINE | ID: mdl-12816549

RESUMEN

BACKGROUND: Bipolar disorder is a lifelong episodic condition characterized by mood swings between mania and depression. Several lines of evidence suggest that serotonin is likely to play a pivotal role in the pathophysiology of bipolar disorder. Ritanserin, a 5-HT2 receptor antagonist, has been reported to have antipsychotic activity. In this 6-week double blind, placebo controlled study involving moderate to severe manic patients, we assessed the effects of ritanserin plus haloperidol in combination with lithium. METHODS: 45 patients aged between 21-43 were eligible to participate as they met the DSM-IV criteria for a current manic episode, on the basis of a clinical interview by an academician psychiatrist. In addition, a score of at least 20 points on the Young Mania rating Scale was required representing moderate to severe mania. Patients were randomly allocated lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)+ ritanserin (10 mg/day) (Group A) or lithium (1-1.2 mEq/L)+ haloperidol (10 mg/day) + placebo (Group B) for a 6-week, double-blind, placebo-controlled study. Patients were assessed by a third year psychiatry resident at baseline and 3, 7, 14, 21, 28 and 42 days after the medication started. All patients entered the hospital were not previously under any medication. The mean decrease in the Young Mania Rating Scale score from baseline was used as the main outcome measure of response of mania to treatment. The extrapyramidal symptoms were assessed using the Extrapyramidal Symptoms Rating Scale. Side effects were systematically recorded throughout the study and were assessed using a checklist. RESULTS: Young Mania Rating Scale total scores improved with ritanserin. The difference between the two protocols was significant as indicated by the effect of group and the between-subjects factor (F = 5.02, d.f. = 1, P = 0.03). The means Extrapyramidal Symptoms Rating Scale scores for the placebo group were higher than the ritanserin group and the difference was significant in day 42. The difference between the two groups in the frequency of side effects was not significant CONCLUSIONS: The efficacy of ritanserin to obtain a better improvement in patients with mania seems to support the 5-HT hypothesis of bipolar disorder.


Asunto(s)
Trastorno Bipolar/tratamiento farmacológico , Haloperidol/uso terapéutico , Litio/uso terapéutico , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Enfermedad Aguda , Adulto , Trastorno Bipolar/fisiopatología , Método Doble Ciego , Quimioterapia Combinada , Humanos , Placebos , Serotonina/fisiología , Resultado del Tratamiento
13.
Drug Saf ; 26(1): 55-64, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12495364

RESUMEN

BACKGROUND: Dysthymia is a prevalent form of subthreshold depressive disorder, associated with considerable disability and high co-morbidity. This paper systematically appraises the evidence for the efficacy and acceptability of the pharmacological treatment for this condition. METHODS: Randomised, controlled trials evaluating the efficacy of drug therapies for dysthymia were included. A comprehensive search of the literature was performed, aiming to avoid publication bias. Pooled relative risks (RR) and 95% CIs were calculated with the Random Effect Model method. The number needed to treat (NNT) and number needed to harm (NNH) were estimated for statistically significant results. RESULTS: Twenty-five trials were included for the main comparisons. Regarding placebo-controlled trials (n = 16), similar results were obtained in terms of efficacy for different groups of drugs, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs) and other drugs (sulpiride, amineptine, and ritanserin). The pooled RR for treatment response was 0.68 (95% CI 0.57-0.81) for TCA and the NNT was 4.3 (95% CI 3.2-6.5); 0.68 (95% CI 0.56-0.82) for SSRIs (NNT 5.1; 95% CI 3.9-7.7); 0.59 (95% CI 0.48-0.71) for MAOIs (NNT 2.9; 95% CI 2.2-4.3). Other drugs (amisulpride, amineptine and ritanserin) showed similar results. The equivalent efficacy between antidepressants as found in trials where active medications were compared confirmed the efficacy findings from placebo trials. In general, patients treated with a TCA were more likely to report adverse events, compared with placebo and SSRIs. CONCLUSIONS: Pharmacotherapy for dysthymia appears to be an effective short-term treatment for dysthymic disorder. Newer antidepressants are equally effective and have better acceptability than TCAs, although their higher cost must be balanced against this assumed advantage.


Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Distímico/tratamiento farmacológico , Antidepresivos/efectos adversos , Antidepresivos Tricíclicos/uso terapéutico , Dibenzocicloheptenos/uso terapéutico , Trastorno Distímico/patología , Humanos , Inhibidores de la Monoaminooxidasa/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo , Ritanserina/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Sulpirida/uso terapéutico , Resultado del Tratamiento
14.
Psychopharmacology (Berl) ; 162(1): 55-62, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12107618

RESUMEN

RATIONALE: Serotonin-2 (5-HT(2)) receptor antagonism has been hypothesized to have antipsychotic activity. However, there has been limited evidence directly linking 5-HT(2) receptor antagonism to symptom control in schizophrenic patients. OBJECTIVES: In order to test this hypothesis this study evaluated the capacity of pretreatment with the 5-HT(2) receptor antagonist ritanserin to attenuate the effects of the 5-HT agonist, m-chlorophenylpiperazine (mCPP). METHODS: Twenty-two male inpatients who met DSM-III-R criteria for schizophrenia or schizoaffective disorder completed 4 test days during which 10 mg ritanserin or matched placebo was administered orally 50 min prior to the intravenous infusion of 0.1 mg/kg mCPP or saline. The test days were conducted in a randomized order under double-blind conditions. RESULTS: mCPP mildly and transiently increased positive symptoms and behavioral activation but not negative symptoms, as assessed by the Brief Psychiatric Rating Scale. mCPP also raised plasma prolactin and cortisol levels. All of these effects were attenuated by ritanserin pretreatment. CONCLUSIONS: These data support a contribution of 5-HT(2) receptor stimulation to symptom exacerbation in schizophrenic patients and a role for 5-HT(2) receptor antagonism in the prevention of this effect.


Asunto(s)
Piperazinas/farmacología , Receptores de Serotonina/fisiología , Ritanserina/farmacología , Esquizofrenia/tratamiento farmacológico , Antagonistas de la Serotonina/farmacología , Adulto , Antipsicóticos/uso terapéutico , Estudios Cruzados , Método Doble Ciego , Humanos , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Análisis de Regresión , Ritanserina/uso terapéutico , Esquizofrenia/sangre , Antagonistas de la Serotonina/uso terapéutico , Agonistas de Receptores de Serotonina/farmacología
16.
Am J Addict ; 10(s1): s3-s15, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11268820

RESUMEN

Neuroscientific underpinnings and pharmacotherapeutic treatments of substance use disorders are rapidly developing areas of study. In particular, there have been exciting new developments in our understanding of the involvement of excitatory amino acid neurotransmitter systems and the opiate and serotonin systems in the pathophysiology of alcohol withdrawal, alcohol dependence, and in subtypes of individuals with alcoholism. In this article, new developments in the pharmacotherapy of alcohol dependence will be reviewed. In particular, the use of anticonvulsants in alcohol withdrawal and protracted abstinence syndromes will be discussed. New data on opiate antagonists and acamprosate, an agent that exerts actions through excitatory amino acid systems in relapse prevention, will be reviewed. Finally, there will be a review of new data concerning the use of serotonin reuptake inhibitors in subtypes of alcoholism and the use of combination pharmacotherapy.


Asunto(s)
Alcoholismo/tratamiento farmacológico , Quimioterapia/tendencias , Acamprosato , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/uso terapéutico , Disuasivos de Alcohol/administración & dosificación , Disuasivos de Alcohol/uso terapéutico , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/uso terapéutico , Buspirona/uso terapéutico , Carbamazepina/administración & dosificación , Carbamazepina/uso terapéutico , Etanol/efectos adversos , Humanos , Naltrexona/administración & dosificación , Naltrexona/análogos & derivados , Naltrexona/uso terapéutico , Antagonistas de Narcóticos/administración & dosificación , Antagonistas de Narcóticos/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Ritanserina/uso terapéutico , Serotoninérgicos/administración & dosificación , Serotoninérgicos/uso terapéutico , Oxibato de Sodio/administración & dosificación , Oxibato de Sodio/uso terapéutico , Síndrome de Abstinencia a Sustancias/etiología , Taurina/administración & dosificación , Taurina/análogos & derivados , Taurina/uso terapéutico , Ácido Valproico/administración & dosificación , Ácido Valproico/uso terapéutico , Vigabatrin/administración & dosificación , Vigabatrin/uso terapéutico
17.
Drug Alcohol Depend ; 61(2): 183-9, 2001 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-11137283

RESUMEN

Eighty cocaine-dependent individuals enrolled in outpatient treatment took part in a randomized, double-blind, placebo-controlled trial of ritanserin, a 5-HT(2) antagonist, as an adjunct therapy. Participants attended an outpatient day hospital therapy program each day and received tablets containing placebo or 10 mg ritanserin for a 4-week period. Primary outcome measures included retention in treatment, urine drug tests, and self-reports of craving. Secondary outcome measures were depression scores on the Beck and Hamilton inventories, negative mood as measured by the Profile of Mood States, and life functioning as measured by the Addiction Severity Index. Although participants showed improvement over the 4 weeks, there were no group differences on any of the measures. These results fail to support the use of ritanserin as a complement to outpatient psychosocial therapy for cocaine dependence.


Asunto(s)
Ansiolíticos/uso terapéutico , Conducta Adictiva/tratamiento farmacológico , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Ritanserina/uso terapéutico , Adulto , Afecto/efectos de los fármacos , Análisis de Varianza , Ansiolíticos/farmacología , Conducta Adictiva/sangre , Conducta Adictiva/psicología , Trastornos Relacionados con Cocaína/sangre , Trastornos Relacionados con Cocaína/psicología , Método Doble Ciego , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Ritanserina/farmacología , Análisis de Supervivencia
18.
Alcohol ; 21(1): 11-7, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10946153

RESUMEN

This study investigated the ability of ritanserin, a 5-HT2 antagonist, to modify ethanol withdrawal (EW) symptoms in two animal models of anxiety: the elevated plus-maze (EPM) and the pentylenetetrazol (PTZ) discrimination assay. Long-Evans hooded rats were given a nutritionally balanced liquid diet containing 4.5% ethanol for 10 days. Twelve hours after removal of the ethanol diet, rats were tested in the EPM. A significant reduction in the open-arm activity and the number of total arm entries was observed, which is indicative of EW. Acute ritanserin (0.16-0.64 mg/kg, i.p., 60 min) had no effect on EW-induced anxiety-like behavior on the EPM. Ritanserin (0.08-0.64 mg/kg, i.p., b.i.d. 12 h) administered concurrently with the last 5 days of ethanol diet produced an increase in the time spent on the open arms of the EPM and reversed the EW-induced reduction in total arm entries. Rats trained to discriminate between saline and PTZ (an anxiogenic drug), selected the PTZ lever during EW. Chronic ritanserin (0.32 mg/kg, i.p., b.i.d. ) did not block PTZ lever responding during EW. On the rotorod, ritanserin (0.32 mg/kg, i.p.) increased the motor incoordination induced by ethanol. In conclusion, coadministration of ritanserin with ethanol prevented the development of EW-induced anxiety as measured by the EPM, but not in the PTZ drug discrimination.


Asunto(s)
Ansiolíticos/uso terapéutico , Ansiedad/tratamiento farmacológico , Depresores del Sistema Nervioso Central/efectos adversos , Etanol/efectos adversos , Ritanserina/uso terapéutico , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Animales , Ansiolíticos/farmacología , Ansiedad/inducido químicamente , Aprendizaje Discriminativo/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Ratas , Ratas Long-Evans , Ritanserina/farmacología
19.
Drug Alcohol Depend ; 59(1): 33-42, 2000 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-10706973

RESUMEN

Eighty-one cocaine-dependent outpatients were assessed for their reactions to cocaine-related cues in a laboratory setting. All subjects contributed a urine sample prior to the session. Compared with non-drug control cues, the cocaine stimuli produced increases in physiological arousal, self-reports of high, craving, and withdrawal, and self-reports of negative mood. Subjects who tested cocaine-positive on the day of testing differed only in skin resistance responding from those who tested cocaine-negative. Changes in cue-induced physiological and self-report measures were also not associated with between-subject variations in mood as measured by the Profile of Mood States (POMS) questionnaire administered prior to cue assessment. Thus, variations in baseline mood and recent cocaine use history do not introduce an additional source of variability in cue reactivity measurements. However, negative mood states at the start of a session were associated with higher levels of self-reported craving, high, and withdrawal both before and after cue exposure.


Asunto(s)
Afecto/efectos de los fármacos , Nivel de Alerta/efectos de los fármacos , Trastornos Relacionados con Cocaína/psicología , Cocaína/administración & dosificación , Cocaína Crack , Motivación , Adulto , Cocaína/efectos adversos , Trastornos Relacionados con Cocaína/rehabilitación , Señales (Psicología) , Esquema de Medicación , Respuesta Galvánica de la Piel/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Ritanserina/uso terapéutico
20.
Pituitary ; 3(2): 55-9, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11141696

RESUMEN

Central serotonergic regulation could have a role in the course of pituitary-dependent Cushing's disease. We studied the effects of ritanserin and ketanserin, two related selective 5HT2 receptor antagonists, in 11 patients with Cushing's disease. Treatment lasted from 1 month to 1 year (up to 4 years in one patient). Daily doses were 10-15 mg for ritanserin, and 40-80 mg for ketanserin. Since the two drugs share the same mechanism of action and no qualitative or quantitative differences in response to their administration were observed, the results were pooled together. Patients were assessed by clinical and hormonal evaluation. Urinary cortisol and ACTH were considered the parameters of interest. Short-term response: after 1 month, there was a significant decrease of urinary cortisol from 781 (160) to 331 (215) nmol/d (P < 0.02) while ACTH was 9.8 (1.5) pmol/L baseline and again 8.8 (2.2) pmol/L at 1 month (P = NS). For 9 patients, hormonal parameters were available after 1 week of treatment. In this case, also ACTH levels were significantly decreased (from 9.6 (1.7) to 5.2 (1.3) pmol/L; P < 0.01) together with urinary cortisol (from 781 (194) to 372 (165) nmol/d; P < 0.01). Long-term response: in 3 patients, hormonal parameters failed to respond to serotonin receptor antagonists, which were thus discontinued. An improvement was recorded in the remaining 8 patients, that was prolonged in 3, and transient in 5. In 3 of these latter patients, a marked increase of ACTH was observed before treatment discontinuation. Ketanserin was given to 2 patients with Nelson's syndrome, with only transient ACTH decrease in one, and no changes in ACTH response to CRH after 1 month treatment in both cases. An inhibitory effect of ritanserin and ketanserin on ACTH and cortisol production in Cushing's disease appeared to be limited both in terms of duration of response and number of patients with a satisfactory outcome. However, the results may provide a better understanding of serotonergic modulation in Cushing's disease and lead to therapeutic developments.


Asunto(s)
Síndrome de Cushing/tratamiento farmacológico , Ketanserina/uso terapéutico , Ritanserina/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Adolescente , Hormona Adrenocorticotrópica/orina , Adulto , Femenino , Hormonas/sangre , Hormonas/orina , Humanos , Hidrocortisona/orina , Ketanserina/efectos adversos , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Síndrome de Nelson/tratamiento farmacológico , Ritanserina/efectos adversos , Antagonistas de la Serotonina/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...